Next 10 |
Start Time: 08:30 End Time: 08:44 Zyla Life Sciences (ZCOR) Q1 2020 Earnings Conference Call May 15, 2020, 08:30 AM ET Company Participants Todd Smith - President and CEO Jesse Neri - SVP, Finance Mark Strobeck - EVP and COO Blair Clark-Schoeb - IR Conference Call Partic...
Zyla Life Sciences ( OTCQX:ZCOR ): Q1 net loss of $18.2M More news on: Zyla Life Sciences, Earnings news and commentary, Healthcare stocks news, , Read more ...
WAYNE, Penn. , May 15, 2020 /PRNewswire/ -- Zyla Life Sciences (OTCQX: ZCOR) ("Zyla" or the "Company"), a commercial-stage life sciences company, today reported financial results for the first quarter ended March 31, 2020 , including net sales from commercial products: SPR...
WAYNE, Pa. , May 1, 2020 /PRNewswire/ -- Zyla Life Sciences (OTCQX: ZCOR) ("Zyla"), a commercial stage life sciences company, today announced that its 2020 first quarter financial results will be released on May 15, 2020 . Following the announcement, Zyla's management will host a li...
Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting Assertio Reaffirms its Ability to Achieve Upwards of $40 Million in Synergies Will Report First Quarter 2020 Financial Results on Monday, May 11, 2020 Prior to the Open of Markets LAKE ...
Zyla Life Sciences (ZCOR) Q4 2019 Earnings Conference Call March 27, 2020 08:30 ET Company Participants Todd Smith - President & CEO Jesse Neri - VP, Finance Mark Strobeck - COO Conference Call Participants Presentation Operator Good morning, ladies and gentleme...
Zyla Life Sciences ( OTCQX:ZCOR ): FY net income of $60.6M Revenue of $81.3M (+167.9% Y/Y) Press Release More news on: Zyla Life Sciences, Earnings news and commentary, Healthcare stocks news, ,
WAYNE, Pa. , March 27, 2020 /PRNewswire/ -- Zyla Life Sciences (OTCQX: ZCOR) ("Zyla" or the "Company"), a commercial-stage life sciences company, today reported financial results for the fourth quarter and full year ended December 31, 2019 , including net sales from commercial ...
Assertio Therapeutics (NASDAQ: ASRT ) and Zyla Life Sciences ( OTCQX:ZCOR ) have agreed to merge in an all-stock transaction. Under the terms of the deal, Zyla stockholders will receive 2.5 shares in the combined company for each Zyla share owned. More news on: Assertio Therapeutics, Inc...
Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive...
News, Short Squeeze, Breakout and More Instantly...
WAYNE, Penn. , May 15, 2020 /PRNewswire/ -- Zyla Life Sciences (OTCQX: ZCOR) ("Zyla" or the "Company"), a commercial-stage life sciences company, today reported financial results for the first quarter ended March 31, 2020 , including net sales from commercial products: SPR...
WAYNE, Pa. , May 1, 2020 /PRNewswire/ -- Zyla Life Sciences (OTCQX: ZCOR) ("Zyla"), a commercial stage life sciences company, today announced that its 2020 first quarter financial results will be released on May 15, 2020 . Following the announcement, Zyla's management will host a li...
Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting Assertio Reaffirms its Ability to Achieve Upwards of $40 Million in Synergies Will Report First Quarter 2020 Financial Results on Monday, May 11, 2020 Prior to the Open of Markets LAKE ...